Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease?

Journal of the Pancreas

Volumn 9, Issue 3, 2008, Pages 283-289

  Weersma, Rinse K ^a   Batstra, Manou R ^b   Kleibeuker, Jan H ^a   van Dullemen, Hendrik M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

Antibodies; Azathioprine; Crohn disease; Inflammatory bowel diseases; Pancreas; Pancreatitis; Serology

Indexed keywords

AMYLASE; AUTOANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DILUTION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; MALE; PANCREATITIS; POST HOC ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; AUTOANTIBODIES; AZATHIOPRINE; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PANCREAS; PANCREATITIS; SEROEPIDEMIOLOGIC STUDIES;

EID: 45749110287     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
2. Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004; 20:843-50.
3. Bajaj JS, Saeian K, Varma RR, Franco J, Knox JF, Podoll J, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005; 100: 1121-5.
4. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-90.
5. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14:181-7.
6. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenctics 2004; 14:779-81.
7. Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mereaptopurine induced myelosuppression. Gut 2005; 54:565.
8. Stöcker W, Otte M, Ulrich S, Normann D, Stöcker K, Jantschek G. Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn's disease and ulcerative colitis. Dtsch Med Wochenschr 1984; 109:1963-9.
9. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991; 32:1192-7.
10. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33:523-8.
11. Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:771-7.
12. Klebl FH, Bataille F, Buy C, Hofstäter F, Schölmerich J, Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol 2005; 17:73-7.
13. Koutroubakis IE, Drygiannakis D, Karmiris K, Drygiannakis 1, Makreas S, Kouroumalis EA. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci 2005; 50:2330-4.
14. Weersma RK, Oostenbrug LE, Nolte IM, Van Der Steege G, Oosterom E, Van Dullemen HM, et al. Association of interleukin-1 receptor-associated kinase M (IPAK-M) and inflammatory bowel diseases. Scand J Gastroenterol 2007; 42:827-33.
15. Verge CF, Stenger D, Bonifacio E, Colman PG, Piicher C, Bingley PJ, Eisenbarth GS. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998; 47:1857-66.
16. Winnock F, Christie MR, Batstra MR, Aanstoot HJ, Weets I, Decochez K, et al. Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (prc)typc 1 diabetes: association with 1A-2 and islet cell autoantibodies. Diabetes Care 2001; 24:1181-6.
17. Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Control Clin Trials 1997; 18:274.
18. Seibold F, Scheurlen M, Müller A, Jenss H, Weber P. Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. J Clin Gastroenterol 1996; 22:202-6.
19. Foitzik T, Forgacs B, Ryschich E, Hotz H, Gebhardt MM, Buhr HJ, Klar E. Effect of different immunosuppressive agents on acute pancreatitis: a comparative study in an improved animal model. Transplantation 1998; 65:1030-6.
20. Vernier G, Sendid B, Poulain D, Colombel JF. Relevance of serologic studies in inflammatory bowel disease. Curr Gastroenterol Rep 2004; 6:482-7.
21. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788-91.
22. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68:1542-8.
23. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020-8.